---
document_datetime: 2023-09-21 20:17:50
document_pages: 39
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/sebivo-h-c-713-r-0023-epar-assessment-report-renewal_en.pdf
document_name: sebivo-h-c-713-r-0023-epar-assessment-report-renewal_en.pdf
version: success
processing_time: 32.7535858
conversion_datetime: 2025-12-19 04:35:52.348874
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

Committee for Medicinal Products for Human Use (CHMP) Assessment report Sebivo telbivudine Procedure No.: EMEA/H/C/000713/R/0023 Note Renewal Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. Medicinal product no longer autho

●

7 Westferry Circus

Telephone

Canary Wharf

●

London E14 4HB

+44 (0)20 7418 8400

Facsimile

●

United Kingdom

+44 (0)20 7418 8409

Website

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

●

7 Westferry Circus

Telephone

Canary Wharf

●

London E14 4HB

+44 (0)20 7418 8400

Facsimile

●

United Kingdom

+44 (0)20 7418 8409

Website

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| Note ............................................................................................................1           |
|------------------------------------------------------------------------------------------------------------------------------|
| Table of contents.........................................................................................3                  |
| 1. Background information on the renewal..................................................4                                  |
| 1.1. Marketing authorisation ...................................................................................... 4        |
| 1.2. Steps taken after the granting of the marketing authorisation / first renewal .............. 4                          |
| 1.3. Renewal application............................................................................................ 7       |
| 1.4. Steps taken for the assessment of the renewal:...................................................... 7                  |
| 2. Scientific discussion ................................................................................8                   |
| 2.1. Introduction ...................................................................................................... 8   |
| 2.2. Quality ............................................................................................................. 9 |
| 2.3. Non-clinical ....................................................................................................... 9  |
| 2.3.1. Pharmacodynamics.......................................................................................... 9          |
| 2.3.2. Pharmacokinetics .......................................................................................... 10        |
| 2.3.3. Toxicology.................................................................................................... 10     |
| 2.4. Clinical efficacy and safety................................................................................. 11        |
| 2.4.1. Clinical efficacy ............................................................................................. 11    |
| 2.4.2. Clinical safety ............................................................................................... 22    |
| 2.5. Risk management plan...................................................................................... 32           |
| 2.6. Changes to the product information .................................................................... 35 longer       |
| 2.7. Overall conclusions and benefit risk balance......................................................... 36                |
| 3. Recommendations.................................................................................38                        |

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 1. Background information on the renewal

## 1.1. Marketing authorisation

The European Commission granted the Marketing Authorisation for Sebivo based on a favourable opinion adopted by the CHMP on 26 April 2007. 1.2. Steps taken after the granting of the marketing authorisation / first renewal Subsequent to the granting of the Marketing Authorisation, the following changes were approved: Medicinal product no longer authorised

<!-- image -->

| No        | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Opinion/ Notification issued on   | Annexes affected 1   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|----------------------|
| IG/0088/G | This was an application for a group of variations. C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system, C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DDPS longer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 11/07/2011                        | no                   |
| IA/0022/G | This was an application for a group of variations. B.II.b.2.b.1 - Change to batch release arrangements and quality control testing of the FP - Not including batch control/testing, A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 05/07/2011                        | yes                  |
| IA/0021/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release), A.7 - Administrative change - Deletion of manufacturing sites, B.II.b.2.b.1 - Change to batch release arrangements and quality control testing of the FP - Not including batch control/testing no                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 09/06/2011                        | yes                  |
| II/0020/G | This was an application for a group of variations.  To change the synthesis of the active substance  To add the new specification parameters to the specification of the active substance with its corresponding test methods.  To delete some test procedures.  To add some manufacture sites for active substance testing. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes place, B.I.a.2.b - Changes in the manufacturing process of the active substance - Substantial change to the manufacturing process of the active substance which may have a significant impact on the quality, safety or efficacy of the medicinal product, B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method, B.I.b.2.b - Change in test procedure for active substance or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised product | 20/01/2011                        | no                   |
| II/0018   | Update of section 5.1 of the SmPC to include information related to 4 year resistance of telbivudine further to the assessment of FUM 020. In addition section 4.8 is updated to be in line with the SmPC guideline. Annex II is updated to delete the reference to the DDPS version number and an editorial change is made to section 5.1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 16/12/2010                        | yes                  |

1 SPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| No        | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Opinion/ Notification issued on   | Annexes affected 1   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|----------------------|
|           | C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                   |                      |
| IG/0032/G | This was an application for a group of variations. C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system, C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DDPS, C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV                                                                                                                                                                                                                                  | 21/12/2010                        | no                   |
| II/0013   | Update of sections 4.3, 4.4 and 4.5 of the SmPC to include a contra- indication related to the combination of telbivudine with standard or pegylated interferon alfa-2a, due to an increased risk of developing peripheral neuropathy. The PL has been updated accordingly. The MAH has also incorporated some updates following the QRD template. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH                                                                                                                                                                                                                                                                   | 21/10/2010 authorised             | yes                  |
| IB/0019   | C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH no longer                                                                                                                                                                                                                                                                                                                                            | 21/09/2010                        | yes                  |
| IB/0017   | B.I.b.2.e - Change in test procedure for active substance or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 15/07/2010                        | no                   |
| IB/0015   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 13/07/2010                        | yes                  |
| IA/0016/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the active substance - Minor change in the manufacturing process of the active substance, B.I.b.2.a - Change in test procedure for active substance or starting material/reagent/intermediate - Minor changes to an approved test procedure, A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance, B.I.a.3.a - Change in batch size (including batch size ranges) of active substance or intermediate - Up to 10-fold increase compared to the currently approved batch size, B.I.a.3.b - Change in batch size (including batch size ranges) of active substance or intermediate - Downscaling product | 08/07/2010                        | no                   |
| IB/0014/G | This was an application for a group of variations.  To extend the shelf life from 24 months to 36 months for Sebivo 20mg/ml oral solution in glass bottle.  To tighten the release specifications for Thymine from nmt 0.5% to nmt 0.2%. B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits, B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                       | 18/06/2010                        | yes                  |

<div style=\"page-break-after: always\"></div>

| No      | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Opinion/ Notification issued on   | Annexes affected 1   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|----------------------|
| II/0011 |  Update of the Detailed Description of the Pharmacovigilance system (DDPS).  Update of DDPS (Pharmacovigilance),  Changes to QPPV                                                                                                                                                                                                                                                                                                                                                           | 18/02/2010                        | yes                  |
| II/0010 | Update of sections 4.4 and 5.2 of the SmPC with regards to rhabdomyolysis in line with information already available in section 4.8 and with data from a PK substudy, following the CHMP's request having assessed follow-up measure 008.4, respectively. The PL is updated in accordance. The MAH also took this opportunity to update contact details of local representatives, to align Annex II with QRD 7.3 template wording and to correct a minor typographical error in the Labelling. | 21/01/2010                        | yes                  |
| IB/0012 | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                         | 11/03/2010 authorised             | no                   |
| II/0009 | Update of section 4.4 of the SPC with regards to switching lamivudine- experienced patients with lamivudine-resistance or experiencing virological failure after at least 24 weeks of treatment with lamivudine. This was requested by the CHMP in April 2009 following the assessment of FU2 011.2 related to the resistance analysis of study NV-02B-01.                                                                                                                                     | 17/12/2009                        | yes                  |
| II/0008 | Update of sections 4.6 and 5.3 of the SPC further to the results of a toxicity study in juvenile rats.                                                                                                                                                                                                                                                                                                                                                                                         | 24/09/2009                        | yes                  |
| II/0006 | Update of section 4.8 of the SPC and section 4 of the PL to include rhabdomyolysis and lactic acidosis following post marketing reports.                                                                                                                                                                                                                                                                                                                                                       | 23/07/2009                        | yes                  |
| IA/0007 | The introduction of a polypropylene oral syringe with graduation as an additional dosing device for Sebivo Oral Solution 43_a_01_ Add./replacement/del. of measuring or administration device - addition or replacement longer                                                                                                                                                                                                                                                                 | 03/03/2009                        | yes                  |
| X/0004  | The MAH applied for the addition of a new pharmaceutical form (20 mg/ml oral solution), in addition to the currently approved pharmaceutical form (film-coated tablets). Annex I_2.(d) Change or addition of a new pharmaceutical form no                                                                                                                                                                                                                                                      | 20/11/2008                        | yes                  |
| II/0005 | To update sections 4.2, 4.4, 4.8 and 5.1 of the SPC based on 104 weeks safety and efficacy data from the Phase III studies NV-02B-007 and NV-02B-015 and data from resistance studies. Furthermore, the MAH took the opportunity of this change to update section 4.5 of the SPC to reflect the lack of pharmacokinetic (PK) interaction with tenofovir as requested by the CHMP following evaluation of the PK study in May 2008. Section 4 of the PL was updated accordingly. product        | 25/09/2008                        | yes                  |
| II/0003 | To update sections 4.4, 4.5 and 4.8 of the SPC to include the adverse reaction peripheral neuropathy with frequency uncommon and to inform prescribers that an increased risk of peripheral neuropathy has been observed when telbivudine and pegylated interferon alfa-2a are co-administered. Sections 2 and 4 of the PL were updated accordingly. The MAH took the opportunity of this change to update the contact details for Slovenia, Slovakia and Latvia.                              | 24/01/2008                        | yes                  |
| IB/0001 | 41_b_Change in pack size - change in fill weight/volume of non- parenteral multid. products                                                                                                                                                                                                                                                                                                                                                                                                    | 22/06/2007                        | yes                  |
| IA/0002 | 07_a_Replacement/add. of manufacturing site: Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                          | 29/05/2007                        | no                   |

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

## 1.3. Renewal application

Pursuant to Article 14 (1-3) of Regulation (EC) No. 726/2004, the Marketing Authorisation Holder Novartis Europharm Ltd., submitted to the Agency on 25 August 2011 an application for renewal of the Marketing Authorisation for Sebivo. The expiry date of the Marketing Authorisation is 26 April 2012.

| The Marketing Authorisation Holder submitted an application for renewal of the Marketing Authorisation on:                                                                        | 25 August 2011                 |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|
| The procedure started on:                                                                                                                                                         | 18 September 2011              |
| The Rapporteur's preliminary assessment report was circulated to all CHMP Members on:                                                                                             | 28 October 2011                |
| During the November 2011 CHMP meeting, the CHMP agreed on a List of Questions (LoQ) relating to clinical issues that was sent to the MAH on:                                      | 18 November 2011               |
| The MAH submitted the responses to the CHMP List of Questions on:                                                                                                                 | 29 and 30 November 2011 longer |
| CHMP discussion and questions referred to HIV/viral CHMP Scientific Advisory Group                                                                                                | 16 December 2011 no            |
| The Rapporteur's and Co-Rapporteur's joint assessment report on the MAH's responses to the CHMP List of Outstanding issues was circulated to all CHMP members on:                 | 3 January 2012                 |
| HIV/Viral CHMP Scientific Advisory Group discussion                                                                                                                               | 9 January 2012                 |
| The Rapporteur's and Co-Rapporteur's updated joint assessment report on the MAH's responses to the CHMP List of Outstanding issues was circulated to all CHMP Members on: product | 12 January 2012                |
| During the January 2012 CHMP meeting, the CHMP agreed on a List of Questions (LoQ) relating to non-clinical and clinical issues that was sent to the MAH on:                      | 19 January 2012                |
| The MAH submitted the responses to the CHMP List of Questions on:                                                                                                                 | 24 January 2012                |

Rapporteur: Philippe Lechat Co-Rapporteur: Ian Hudson 1.4. Steps taken for the assessment of the renewal: The Marketing Authorisation Holder submitted an application for renewal of the Marketing Authorisation on: The Rapporteur's preliminary assessment report was circulated to all CHMP Members on: During the November 2011 CHMP meeting, the CHMP agreed on a List of Questions (LoQ) relating to clinical issues that was sent to the MAH on: The MAH submitted the responses to the CHMP List of Questions on: CHMP discussion and questions referred to HIV/viral CHMP Scientific Advisory Group The Rapporteur's and Co-Rapporteur's joint assessment report on the MAH's responses to the CHMP List of Outstanding issues was circulated to all CHMP members on: 3 January 2012 9 January 2012 The Rapporteur's and Co-Rapporteur's updated joint assessment report on the MAH's responses to the CHMP List of Outstanding issues was circulated to all CHMP Members on: 12 January 2012 During the January 2012 CHMP meeting, the CHMP agreed on a List of Questions (LoQ) relating to non-clinical and clinical issues that was sent to the MAH on: The Rapporteur's and Co-Rapporteur's joint assessment report on the MAH's responses to the CHMP List of Outstanding issues was circulated to all CHMP members on: Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| The Rapporteur's and Co-Rapporteur's updated joint assessment report on the MAH's responses to the CHMP List of Outstanding issues was circulated to all CHMP Members on:   | 13 February 2012   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| The CHMP, during its January 2012 plenary meeting, issued a positive Opinion on the renewal of the Marketing Authorisation on:                                              | 16 February 2012   |

Consequently, this renewal application includes new and expanded information about the clinical benefit/risk profile of Sebivo accrued during the reporting period from 01 March 2007 to 30 June 2011 along with a proposal for narrowing the indications by describing the patient population most likely to achieve a better response to treatment with minimal resistance and to provide guidance to physicians to modify therapy if undetectable serum hepatitis B virus (HBV) DNA of viral load is not achieved after 24 weeks of treatment.

2. Scientific discussion 2.1. Introduction Sebivo (INN: telbivudine; LDT) is a synthetic thymidine nucleoside analogue with activity against HBV DNA polymerase. Telbivudine-5'-triphosphate inhibits HBV DNA polymerase (reverse transcriptase) by competing with the natural substrate, thymidine 5'-triphosphate, resulting in inhibition of HBV replication. Sebivo is currently indicated for the treatment of chronic hepatitis B (CHB) in adult patients with compensated liver disease and evidence of viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis. Sebivo was first registered in Ghana on 13 July 2006 and received market authorization in Switzerland on 21 August 2006 (the latter date is considered to be the international birth date of the product). It received market authorization in the EU on 24 April 2007. It is currently approved in 109 countries worldwide as a tablet formulation under the trademark Sebivo, except in Chile and the United States, where it is approved under the trademark Skebivo and Tyzeka, respectively. An oral solution formulation has also been developed and is currently registered in 24 countries and the EU. In the setting of variation II-18 (opinion adopted in December 2010) dealing with the 4 years resistance data, it was stressed that the resistance to telbivudine had reached the worrying level of 40% in HbeAg positive and 20% in HbeAg negative patients at 4 years. The low genetic barrier of the Sebivo combined with a problematic safety profile (notably creatinine phosphokinase (CPK) elevation and muscle disorders) questioned the adequacy of this medicinal product in first line therapy. Therefore, the MAH was requested to discuss to what extend Sebivo is considered a treatment option in the current treatment landscape. In response to this request (FUM 050), the MAH proposed to restrict the indication based on baseline HBV DNA/ALT levels and Week 24 on-treatment response in order to improve benefits beyond those observed in the overall pivotal study population while reducing the risk of resistance development. The CHMP noted the proposal and concluded that, with additional details and clinical data to substantiate the proposal, the final conclusion on the benefit/risk assessment of Sebivo will be performed within the forthcoming renewal procedure. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 2.2. Quality

The Marketing Authorisation Holder has confirmed that the quality, with respect to the method of preparation and control, has been regularly updated by variations to take account of technical and scientific progress in accordance with article 16(1) of Regulation (EC) No 726/2004 and that the product conforms to current CHMP quality guidelines.

Concerning Module 3, the MAH has submitted the relevant documents required for the application for renewal such as quality expert statement, including currently authorised specifications for the active substance and the finished product and qualitative and quantitative composition in terms of the active substance and the excipients, statement of GMP compliance, list of variations granted since authorisation, chronological list of follow-up measures submitted and the proposed texts for SmPC, outer and inner labelling and package leaflet. There are no outstanding quality issues. All the relevant sites of manufacture and testing are undergoing regular GMP inspections by an EEA competent authority or MRA partner authority and satisfactory GMP compliance of these sites has been confirmed by the MAH by submission of the appropriate documentation. Appropriate declarations have been submitted concerning the GMP compliance status of the active substance manufacturer(s). The quality of Sebivo continues to be considered acceptable. 2.3. Non-clinical Non-clinical In this renewal application, an update has been provided on non-clinical information of Sebivo based on data generated over the reporting period from 01 March 2007 to 30 June 2011 from internal preclinical studies and published literature. The in vivo non-clinical studies in animals and in vitro studies with animal-derived or human-derived material performed by the MAH or its designees are summarised. The literature published during the review period is also included, with literature searches conducted to identify any publications related to the pharmacology, pharmacokinetics, or toxicity of Sebivo or its active ingredient (telbivudine) during the reporting period. 2.3.1. Pharmacodynamics Primary pharmacodynamics During the reporting period (01 March 2007 until 30 June 2011), Seifer et al 2009 reported that telbivudine, a nucleoside analogue inhibitor polymerase, has a different cross-resistance profile than the nucleotide analogue inhibitors adefovir and tenofovir. The activity of telbivudine against A181V, a mutation in the HBV polymerase gene associated with resistance to adefovir was further assessed in vitro [(RD-2009-50084)]. Compared to the known telbivudine-resistant mutation, M204I, which reduced its activity by &gt;1000-fold, A181V caused only a small increase (4.1-fold) of IC50 with telbivudine. Secondary pharmacodynamics Medicinal product no longer authorised

Telbivudine has not been found active against any virus other than HBV-related hepadnaviruses as described in the original submission. During the reporting period (01-Mar-2007 until 30-Jun-2011), the activity of telbivudine was further investigated in vitro with temporally and geographically distinct wildtype and multidrug-resistant HIV-1 clinical isolates (Lin et al 2010). No inhibition was observed with up

<div style=\"page-break-after: always\"></div>

to 600 μ M of the drug, which supports further exploration of telbivudine as a therapeutic option for HBV in HIV-1 co-infected patients.

## Pharmacodynamic drug interactions

As described in the original submission, there was no negative interaction in terms of anti-HIV or antiHBV activities in vitro between telbivudine (LDT600) and seven FDA-approved nucleoside reverse transcriptase inhibitors (NRTIs), lamivudine (3TC, lam), abacavir (ABC), zidovudine (AZT), stavudine (D4T), 2 ′ , 3 ′ -dideoxyinosine (DDI), emtricitabine (FTC) and tenofovir (TFV). No additional study was performed during the reporting period. 2.3.2. Pharmacokinetics Drug interactions In vitro assessment of liver microsomal cytochrome P450 (CYP450) induction potential of LDT600 (telbivudine) was conducted in primary cultures of human hepatocytes (Study 3210-0720-1800). Telbivudine (0.334, 3.34, and 33.4 μ g/mL) and known CYP450 inducers, 3-methylcholanthrene (3MC), phenobarbital (PB), and rifampicin (RIF) were incubated in cultures of human hepatocytes from three separate donors for three consecutive days. Microsomes were isolated and activities of CYP1A2, CYP2B6, CYP2C9, and CYP3A4 were determined using selective metabolite markers. For each of the three positive controls mentioned above, mean induction data were generated and from those means, the corresponding mean vehicle control values were subtracted, to yield 'adjusted positive control responses'. Induction results from telbivudine assays were averaged from triplicate samples and compared to the corresponding adjusted positive controls. The percent positive control induction level is arbitrarily set at 100% for the positive control specific to a given enzyme. Overall, the results of this study suggest that treatment of primary cultures of human hepatocytes with telbivudine is not associated with induction of liver microsomal CYP1A2, CYP2B6, CYP2C9, and CYP3A4 via assessment of enzyme activity under the concentrations examined. Therefore, these results indicate that there is low potential for drug-drug interactions with telbivudine due to enzyme induction of CYP1A2, CYP2B6, CYP2C9, and CYP3A4. No other additional studies or relevant publications were issued during the reporting period on the pharmacokinetic aspects. 2.3.3. Toxicology In vitro mechanistic studies to examine the effects of telbivudine (LDT600) on mitochondrial function demonstrated that treatment of rat and human hepatocytes, skeletal muscle, or neuron cells with telbivudine at concentrations that is relevant to, or largely exceed the therapeutically relevant levels in human plasma was not associated with mitochondrial toxicity. Additionally, model validation study demonstrated that telbivudine was extensively phosphorylated to its active triphosphate form (5'triposphate telbivudine) in all human cell models used in the in vitro studies. Additionally, results from the in vitro neuronal toxicity studies demonstrated that telbivudine at concentrations largely exceed the therapeutically relevant levels in human plasma did not cause either cytotoxicity or mitochondrial toxicity in SH-SY5Y cells. Medicinal product no longer authorised

The juvenile toxicity study and the follow up juvenile fertility study demonstrated reduced fertility when treated males were paired with treated females, but had no adverse effects on fertility on treated males when paired with untreated female, or treated female paired with untreated males. These results, although showing slightly different NOAELs for fertility effects in different studies, are still

<div style=\"page-break-after: always\"></div>

consistent with the overall conclusion that telbivudine may cause reduced fertility in adult animals and in juvenile animals.

## Discussion and conclusion on non-clinical data

<!-- image -->

The low potential for drug-drug interaction and the slightly reduced activity of telbivudine on A181V (one of the ADV resistance signature mutations) are appropriately reflected in the Sebivo SmPC. The possibility of reduced fertility as observed in adults and juvenile animals are also reflected. Additional activities have also been provided to provide further confidence on the absence of anti-HIV activity of telbivudine in vitro which were the starting point for in vivo exploration. A study in HIV-HBV coinfected patients is planned and should start Q1 2012. Finally, a series of in vitro and in vivo studies in various experimental models have been carried out to clarify the mechanisms underlying the muscular and neuronal adverse events reported in patients treated with Sebivo. Despite being negative, the studies were judged insufficient to exclude a risk of mitochondrial toxicity in patients treated with Sebivo due notably to the fact that limited experience is available with the experimental model used in these studies. Going beyond these conclusions seemed difficult and given that the toxicity has already been identified in vivo , no further in vitro study was deemed necessary. There are no outstanding non-clinical issues. 2.4. Clinical efficacy and safety 2.4.1. Clinical efficacy Clinical Efficacy Below are presented the clinical studies performed by the MAH during the review period, as well as other studies published in scientific journals in order to assess the overall efficacy of Sebivo in its approved indication, and new or expanded information about the clinical benefit. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 1. Overview of Novartis-sponsored Sebivo clinical trials completed within the review period

<!-- image -->

Protocol number / Reference(s)

Study description

Treatment(s) / No. of Main outcome(s) patients/ Duration

## Large patient population

CLDT600ACN03/

Open-label phase IV study of LDT in Chinese patients with HBeAg-positive or HBeAg-

LDT 600 mg/dlay 2211 patients 52 weeks

One-year treatment with LDT in a large CHB patient population demonstrated

CLDT600ACN03CSR CLDT600ACN03

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 3. Overview of efficacy data from non-Novartis sponsored studies

<!-- image -->

| longer   |
|----------|
| no       |
| product  |

Combination therapy has been explored. Combined use of Sebivo with peginterferon led to an increased risk of peripheral neuropathy (a contra-indication has been added to the SmPC via the variation II-13, adopted in October 2010 - see also Clinical safety section below). Add-on adefovir was first investigated but the most recent studies now explore intensification strategy with the more potent drug tenofovir ('Roadmap concept').

In line with the clinical development of Sebivo, most of the studies performed with the medicinal product since its initial MA were conducted in Asian patients. One study, performed in fulfilment of the MAH's commitment made at the time of the MA, is on-going in European countries (study CLDT600A2409). Another study is planned in HIV-HBV co infected patients who do not require Highly Active Antiretroviral Therapy (HAART). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

The MAH has performed a study in decompensated patients comparing telbivudine to the outdated lamivudine.

##  Viral kinetics

The efficacy of telbivudine in early viral suppression was demonstrated in the pivotal study NV-02B007/GLOBE and was confirmed in 2 additional studies, CLDT600A2407 and CLDT600AHK01. These studies also demonstrated that telbivudine has similar anti-viral potency as entecavir and tenofovir over 12 weeks of treatment.  Efficacy in treatment-naive patients with compensated CHB Predictors of efficacy: baseline data and early on-treatment Week 24 response Recent studies have identified the baseline characteristics and early on-treatment responses that correlate with long-term efficacy responses and lower resistance development. Outcomes of 2-year treatment with telbivudine in patients from the NV-02B-007/GLOBE trial were analyzed retrospectively according to serum HBV DNA and ALT levels at baseline and on-treatment responses after 24 weeks (Zeuzem et al 2009).  For baseline predictors, it was observed that baseline HBV DNA &lt;9 log10 copies/ml and ALT ≥ 2×ULN in HBeAg-positive patients and baseline HBV DNA &lt;7 log10 copies/ml in HBeAg-negative patients were associated with favorable outcomes at year 2. After initiation of telbivudine treatment, undetectable serum HBV DNA at treatment Week 24 was the strongest predictor of favourable outcomes at year 2 in both HBeAg-positive and HBeAg-negative patients. In addition, a survey of 2023 CHB patients seen in clinical practices in France, Germany, Italy and Spain (Berg et al 2010) reported that patients were predominately HBeAg-negative (64%). However, few patients presented with high viral load at treatment initiation (97% of HBeAg-positive patients had baseline HBV DNA ≤ 9 log10 copies/ml and 81% of HBeAg-negative patients had HBV DNA &lt;7 log10 copies/ml), and a majority of patients had elevated baseline ALT ≥ 2×ULN (72% of HBeAg-positive and 66% of HBeAg-negative patients). These patient characteristics are in line with the results of NV-02B007/GLOBE study described above (Zeuzem et al 2009), suggesting that the baseline predictors of optimal outcomes as identified in the NV-02B-007/GLOBE study are indeed relevant for the optimal management of CHB patients seen in European clinical practice. On this basis and as proposed following the assessment of the variation II-18 (FUM 050), in order to improve benefits while minimizing risk of resistance development, the MAH proposed within this renewal application to narrow the Sebivo indication according to baseline HBV DNA/ALT levels and Week 24 on-treatment response with treatment intensification (Roadmap Concept) (see Discussion and Conclusion on Efficacy hereafter for further details and discussion on this proposal). Long-term anti-viral efficacy Anti-viral efficacy of telbivudine was maintained during the 3rd to 6th year of telbivudine treatment, as demonstrated in 2-year extension study CLDT600A2303 (3 and 4 year data), the 52-week follow-on study CLDT600ACN04 (5 year data) and the 52-week extension study CLDT600ACN04E1 (6 year data). Study CLDT600A2303 Medicinal product no longer authorised

Study CLDT600A2303 was an open-label extension study in patients with compensated CHB who were previously treated with telbivudine for 2 years in a prior feeder study (including NV-02B-007/GLOBE and NV-02B-015). These patients were treated with telbivudine for an additional 2 years in study CLDT600A2303 and provided cumulative efficacy and safety data after 3 and 4 years of continuous telbivudine therapy (CLDT600A2303 CSR).

<div style=\"page-break-after: always\"></div>

Table 4. Patients with undetectable HBV DNA at Week 24 had better outcomes at 3 and 4 years.

|                                                                                            | Week 52         | Week 104        | Week 156        | Week 208        |
|--------------------------------------------------------------------------------------------|-----------------|-----------------|-----------------|-----------------|
| HBeAg-positive patients (n = 293*)                                                         |                 |                 |                 |                 |
| Maintained undetectable HBV DNA (< 300 copies/ml)                                          | 70.3% (206/293) | 77.3% (218/282) | 75.0% (198/264) | 76.2% (163/214) |
| Maintained undetectable HBV DNA (< 300 copies/ml) with undetectable HBV DNA at week 24     | 99.4% (161/162) | 94.9% (150/158) | 86.7% (130/150) | 87.9% (109/124) |
| Cumulative HBeAg seroconversion rates (%)                                                  | 27.6% (81/293)  | 41.6% (122/293) | 48.5% (142/293) | 53.2% (156/293) |
| Cumulative HBeAg seroconversion rates in patients with undetectable HBV DNA at week 24 (%) | 40.1% (65/162)  | 52.5% (85/162)  | 59.3% (96/162)  | 65.4% (106/162) |
| Maintained ALT normalisation                                                               | 81.4% (228/280) | 87.5% (237/271) | 82.9% (209/252) | 86.4% (178/106) |
| HBeAg-negative patients (n = 209*)                                                         |                 |                 |                 |                 |
| Maintained undetectable HBV DNA (< 300 copies/ml)                                          | 95.2% (199/209) | 96.5% (195/202) | 84.7% (160/189) | 86.0% (141/164) |
| Maintained undetectable HBV DNA (< 300 copies/ml) with undetectable HBV DNA at week 24     | 97.8% (175/179) | 96.5% (166/172) | 86.7% (143/165) | 87.5% (126/144) |
| Maintained ALT normalisation                                                               | 80.3% (151/188) | 89.0% (161/181) | 83.5% (142/170) | 89.6% (129/144) |

<!-- image -->

* The population without viral resistance at entry into study CLDT600A2303 consisted of 502 patients (293 HBeAgpositive and 209 HBeAg-negative). Studies CLDT600ACN04 and CLDT600ACN04E1 Study CLDT600ACN04 was an open-label follow-on study of Chinese patients from study CLDT600A2303 who had undetectable HBV DNA at the end of the 4-year treatment with telbivudine. Patients were treated with telbivudine for an additional year in this study and provided cumulative efficacy and safety data after 5 years of continuous telbivudine therapy. In the ITT population (N=97; 67 HBeAg-positive and 30 HBeAg-negative), 93.7% of HBeAg-positive patients and 96.4% of HBeAg-negative patients maintained undetectable HBV DNA at year 5 (Jia et al 2011). ALT normalization was achieved in 84.6% and 79.3%, respectively. After study CLDT600ACN04, patients were allowed to continue telbivudine for an additional year (total of 6 years) in the extension study CLDT600ACN04E1. In the ITT population (N=66; 43 HBeAg-positive and 23 HBeAg-negative) of CLDT600ACN04E1, 90.7 % of HBeAg-positive patients and 87.0% of HBeAg-negative patients maintained undetectable HBV DNA at year 6 (overall 89.4%) (CLDT600ACN04E1 CSR). HBeAg seroconversion Study CLDT600A2303 Overall, results from NV-02B-007/GLOBE, NV-02B-015 and CLDT600A2303 studies show that HBeAg seroconversion rate increased with duration of treatment: 27.6% at year 1, 41.6% at year 2, 48.5% at year 3, and 53.2% at year 4 in 293 per-protocol HBeAg-positive patients without resistance at entry to CLDT600A2303 (Jia et al 2010). Medicinal product no longer authorised

## Studies CLDT600ACN04 and CLDT600ACN04E1

In study CLDT600ACN04, the cumulative rate of HBeAg seroconversion over 5 years was 67.2% (Jia et

<div style=\"page-break-after: always\"></div>

al 2011). In study CLDT600ACN04E1, 79.1% achieved HBeAg seroconversion cumulatively over 6 years.

## HBsAg seroconversion

<!-- image -->

Study CLDT600A2303 For patients treated in NV-02B-007/GLOBE and CLDT600A2303 studies, telbivudine therapy reduced mean (± SD) serum HBsAg levels from 3.8 ± 0.6 log10 IU/ml at baseline to 3.0 ± 1.4 log10 IU/ml at year 3 (p&lt;0.0001) in 162 HBeAg-positive patients who had undetectable HBV DNA at year 2 (Wursthorn et al 2010). A total of 9/162 (6%) patients achieved HBsAg loss at year 3. Studies CLDT600ACN04 and CLDT600ACN04E1 In study CLDT600ACN04 (ITT population, N=97), 6 (6.2%) patients showed HBsAg clearance, with 3 (3.1%) of these patients also achieving HBsAg seroconversion after 5 years of treatment (Jia et al 2010). At year 5, i.e. baseline of study CLDT600ACN04E1 (ITT population, N=66), the cumulative rate of HBsAg loss and HBsAg seroconversion was 6.1% (4 patients) and 4.5% (3 patients), respectively. Study CLDT600A2410 In study CLDT600A2410, which has applied the roadmap concept of telbivudine therapy with add-on tenofovir at treatment week 24, the rate of HBsAg clearance after 1 year was 6% in the overall mITT population (N=101) and 11% in patients with treatment intensification (CLDT600A2410 FIR; Piratvisuth et al 2011a). Sustained efficacy after discontinuation of treatment Study CLDT600A2303 included patients with compensated CHB who had discontinued telbivudine treatment in NV-02B-007/GLOBE study because they had achieved an efficacy response (i.e. HBV DNA &lt;5 log10 copies/mL and HBeAg loss for at least 24 consecutive weeks) that allowed for per-protocol treatment discontinuation and in line with recommendations in current practice guidelines. These patients were followed for a median time of 120 weeks in NV-02B-007/GLOBE, NV-02B-015 and CLDT600A2303 studies to evaluate off-treatment efficacy and safety outcomes. At Week 104 of off-treatment observation in study CLDT600A2303, the majority of HBeAg-positive patients who had received telbivudine in study NV-02B-007/GLOBE or NV-02B-015 showed sustained HBeAg loss (83.3%, 25/30), sustained HBeAg seroconversion (79.2%, 19/24), sustained virologic response (58.5%) and sustained HBV DNA suppression (55.8%). Patients with sustained HBeAg seroconversion had a mean HBV DNA of 3.3 log10 copies/mL and 73.7% had HBV DNA &lt; 4 log10 copies/mL at Week 104 (CLDT600A2303 Sustainability Report). The MAH proposes in this renewal application to update the section 5.1 of the Sebivo SmPC with these 208-week data on off-treatment sustained efficacy results (see also section 2.6 Changes to the Product Information hereafter). Liver histology improvement Limited data are available on the impact of long-term viral suppression on liver histology and patient outcome. Medicinal product no longer authorised

In study CLDT600ACN04E1, 70 patients with CHB (all Chinese, 47 HBeAg-positive, 23 HBeAg-negative) were evaluated for changes in liver histology and virologic parameters. This was an open-label, singlearm study that included patients who previously completed from 4 to 5 years of treatment.

<div style=\"page-break-after: always\"></div>

A total of 57 patients (38 HBeAg-positive and 19 HBeAg-negative) had paired biopsies at baseline and year 5. The main findings (CLDT600ACN04E1 CSR) are as follows:

-   Resolution of liver inflammation: mean change from baseline to year 5 in Knodell HAI score was -6.3 ± 2.8 and 98.2% (56/57) had absence of liver inflammation (Knodell score ≤ 3; no or minimal necroinflammation) at year 5 compared to 84.2% (48/57) with Knodell score ≥ 4 at baseline before treatment initiation.

The MAH has been requested to investigate whether telbivudine exhibits anti-HIV activity in vitro before initiating clinical trials in HIV co-infected patients.

·   Fibrosis regression: mean change from baseline in Ishak fibrosis score was -1.3 ± 1.3 and 84.2% (48/57) had absence of liver fibrosis (Ishak score ≤ 1; no or minimal fibrosis) at year 5 compared to 75.4% (43/57) with Ishak score ≥ 2 at baseline. ·   Among patients with baseline Ishak fibrosis score ≥ 2, 83.7% (36/43) achieved an Ishak fibrosis score of 0 or 1 (no or minimal fibrosis) after 5 years of treatment. ·   In 6 (10.5%) patients who had advanced fibrosis or cirrhosis (Ishak score 4-6) at baseline, the Ishak score was reduced by a median of 3.0 (range 1-3) points at year 5. ·   Virologic and biochemical responses at year 5 (at entry to study CLDT600ACN04E1) for the 57 patients with paired biopsies: HBV DNA was undetectable in 98.2% of patients, cumulative HBeAg loss/seroconversion in 86.8%/78.9%, cumulative HBsAg loss/seroconversion in 5.3%/3.5%, and ALT normalization in 79.6%. Therefore, the profound and durable viral suppression with telbivudine over 5 years was associated with an improvement in liver histology, reaching the long-term goals of treatment in patients with CHB. The MAH proposes in this renewal application to update the section 5.1 of the Sebivo SmPC with these liver histology study results (see also section 2.6 Changes to the Product Information hereafter).  Efficacy in special populations Decompensated CHB patients Telbivudine is not currently indicated for use in patients with decompensated CHB. However, results from the 2-year double-blind, randomized study CLDT600A2301, the largest randomized controlled trial performed to date in patients with decompensated CHB (n=114 in LDT group and 114 in LAM group) shown the superior benefits of telbivudine vs. lamivudine in patients with decompensated CHB. It was noted that neither of these medicinal products can be considered as an optimal option in patients with decompensated disease nowadays, especially when considering that virological breakthrough could be associated with a more pejorative evolution of the disease. Medicinal products with high genetic barrier for resistance are mandatory in this sensible population. HIV/HBV co-infection Telbivudine is not currently indicated for use in patients co-infected with HIV. Due to the high risk of HIV resistance, the monotherapy of antivirals with dual efficacy on HIV and HBV (e.g. emtricitabine, lamivudine, tenofovir, or entecavir) without a full combination antiretroviral regimen should be avoided in HIV/HBV co-infected patients (DHHS HIV Guidelines 2011). Medicinal product no longer authorised

Telbivudine did not exhibit anti-HIV activity in the in vitro investigations performed by the MAH. However extrapolation of the in vitro observations to in vivo situations requires caution, especially

<div style=\"page-break-after: always\"></div>

when considering that the case-report of a patient who experienced significant suppression of HIV viral load under telbivudine had been reported (CROI 2009). Therefore, a pilot study with sequential inclusion of HIV-HBV co-infected patients has been requested to determine whether telbivudine had an activity on HIV in vivo before a larger study in HIV/HBV infected patients could be performed.

The study is planned with first inclusion scheduled for February 2012. The target population is patients with hepatitis B virus and HIV-1 who require treatment for chronic hepatitis B but are not yet eligible for HAART. Whether telbivudine had no activity against HIV and could be regarded as a valid option in HIV-HBV co-infected patients not in need of HAART remains to be confirmed. Treatment-experienced patients The MAH referred to data from two clinical studies (CLDT600A2303 and CLDT600A2402) in order to demonstrate the efficacy of telbivudine in patients who switched from lamivudine to telbivudine treatment. In addition, studies CLDT600A2304 and CLDT600A2303A1 are provided as showing the efficacy of telbivudine in combination with adefovir in patients who previously failed on anti-viral monotherapy. It noted that in the setting of the variation II-09 (adopted in December 2009) and as reflected in the SmPC, telbivudine monotherapy is not considered an option for patients with established lamivudineresistant hepatitis B virus infection. Patients who failed to achieve virological response following treatment with lamivudine for more than 24 weeks are unlikely to benefit from telbivudine monotherapy. Furthermore the CHMP consider that there is currently no clinical data to properly assess the benefit and risk of switching to telbivudine for lamivudine-treated patients who achieve complete viral suppression on lamivudine. When considering that lamivudine is a well-tolerated drug, there is no reason for switching from lamivudine to telbivudine a patient stable under lamivudine. Study CLDT600A2304: Combination therapy Study CLDT600A2304 was a randomized, open-label study of telbivudine in combination with adefovir (ADV) vs. ADV monotherapy in patients with HBeAg-positive CHB and confirmed resistance (YMDD mutation) to prior lamivudine treatment. The study was terminated early, with agreement from the EMA on 01 February 2008, primarily due to difficulties enrolling patients into the ADV monotherapy arm. Study CLDT600A2303A1: Combination therapy Study CLDT600A2303A1 was an open-label study of telbivudine and adefovir  in patients with CHB who had failed to achieve or maintain undetectable HBV DNA after 8 months of LDT monotherapy in a previous qualifying study CLDT600A2303. The CHMP considers that medicinal products with high potency and high genetic barrier to resistance should be preferred for the management of treatment-experienced patients. Due to its low genetic barrier and safety profile, telbivudine cannot be regarded as an interesting option for combination therapy. Post-transplant patients Medicinal product no longer authorised

In a 12-month study of 13 patients (8 HBeAg-positive, 5 HBeAg-negative) infected with HBV after undergoing OLT, 3 patients had undetectable HBV DNA and 10 had HBV DNA &gt;10 4  copies/mL at baseline (Gerasimova et al 2011). Following telbivudine treatment, HBV DNA was undetectable in 60% (6/10) at 6 months and 90% (9/10) at 12 months. HBeAg seroconversion was achieved in 2 of 8 HBeAg-positive patients at baseline and HBsAg loss in 23% (3/13). ALT normalization was achieved in 80% of patients after 3 months. Telbivudine was well-tolerated as evidenced by absence of serious

<div style=\"page-break-after: always\"></div>

adverse events and discontinuations, neutropenia, creatine kinase elevations, ALT flares, renal impairment (GFR) and myopathy.

## Paediatric patients

CLDT600A2414 is an ongoing, cross-sectional, global, non-interventional epidemiology survey of HBV infection in children and adolescents (2 to ≤ 18 years). (Kelly et al 2011).

This large global epidemiology survey showed that paediatric CHB infection is largely HBeAg positive and affects mostly patients aged &gt;7 years, reflecting the impact of vaccination programs introduced worldwide. Most patients had slow disease progression over the last 12 months. These results highlight the difficulty of conducting paediatric studies in patients with decompensated CHB or in children aged &lt;7 years due to low prevalence. Nonetheless, results from this study show that despite the advent of successful infant and adolescent immunization programs in many countries, the burden of hepatitis B in children and adolescents remains high worldwide and warrants further study to find safe and effective treatment options.  Resistance The MAH has undertaken an analysis of resistance development using the published mathematical model by Pawlotsky et al 2008. Resistance was analyzed for years 1 and 2 using data from the pivotal NV-02B-007/GLOBE trial, followed by analysis for years 3 and 4 using data from the open-label, 2-year extension study CLDT600A2303. In the new analysis, applying the mathematical model by Pawlotsky et al 2008, the cumulative resistance rate over the 2-year, double-blind treatment period in the NV-02B-007/GLOBE trial is 13.7% for HBeAg-positive patients and 6.8% for HBeAg-negative patients. These year 2 rates recalculated as per the mathematical model by Pawlotsky et al are much lower than the rates (25.1% for HBeAg-positive patients and 10.8% for HBeAg-negative patients) reported in the currently approved Sebivo SmPC, which were based on a 2-year analysis of NV-02B-007/GLOBE data that included all 680 patients irrespective of the patient's PCR status at the beginning of year 2. Table 5. Cumulative genotypic resistance at 1 and 2 years (confirmed by viral breakthrough) by HBeAg status using the mathematical model of Pawlotsky et al in patients from the NV-02B007/GLOBE trial Resistance rates at 1 and 2 years in defined patient subgroups Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 6. Efficacy responses and resistance rates at years 1 and 2 stratified by baseline characteristics and early on-treatment response at Week 24

|                 | HBeAg-positive   | HBeAg-negative²   | HBeAg-negative²   |
|-----------------|------------------|-------------------|-------------------|
| Year 1/Week 523 |                  |                   |                   |

Cumulative resistance at 3 and 4 years As per the mathematical model by Pawlotsky et al, the analysis at years 3 and 4 includes only those patients who were PCR-negative at the beginning of the respective year. Using this method, the cumulative resistance rate over 4 years of treatment in patients from the NV-02B-007/GLOBE trial is 20.0% overall, 22.3% for HBeAg-positive patients and 16.0% for HBeAg-negative patients. Table 7. Genotypic resistance (confirmed by viral breakthrough): annual rate and cumulative rate (calculated using the mathematical model byPawlotsky et al) in patients from NV-02B-007/GLOBE trial Medicinal product no longer authorised

The 4-year cumulative resistance rate of 22.3% for HBeAg-positive patients calculated using the published mathematical model by Pawlotsky et al is considerably lower than the 41% currently reflected in the SPC (Section 5.1 on Pharmacodynamic Properties). Also, the 4-year cumulative rate is

<div style=\"page-break-after: always\"></div>

even lower for HBeAg-negative patients (16.0%) who constitute the majority of CHB patients in Europe.

The CHMP noted that, even though substantially decreased with the Pawlotsky method, the risk of resistance for telbivudine remains a concern and is likely to be approx 10-fold higher as compared to that with entecavir.

Discussion and Conclusion on Efficacy Even though substantially decreased with the Pawlotsky method, the risk of antiviral resistance for telbivudine remains a concern. In order to minimize this higher risk of resistance, the MAH is proposing in this renewal application to define patient subgroups at lower risk of developing resistance and for which a treatment initiation with telbivudine monotherapy would not represent a sub-optimal management as compared to tenofovir or entecavir. Based on the clinical efficacy data described above (see efficacy in treatment-naïve patients with compensated CHB), the MAH suggests to restrict the use of telbivudine to patients with favourable baseline characteristics (i.e. baseline HBV DNA&lt;9log10 copies/ml and ALT ≥ 2x ULN in HBeAg+ and HBV DNA&lt;7log10 copies/ml in HBeAg- patients) and propose intensification (Roadmap concept) if viral suppression is not achieved after 24 weeks. The CHMP agreed that in these patients subgroups, risk of resistance was lower (resistance rate 1.8% in HBeAg+ and 2.3% in HbeAg- patients at 2 years). However it noted that those rates are still higher than those reported with tenofovir or entecavir (no resistance found at 4 years for tenofovir, resistance found in 0.5% at year 2 and in 1.2% of patients at year 5 for entecavir). It was also noted that 30% of HBeAg+ and 5% of HBeAg- would not achieve undetectable HBV DNA at week 24 with telbivudine and therefore will require intensification. On the contrary, for tenofovir or entecavir, intensification is not needed for the majority of patients with partial virological response (as suggested in recent literature for entecavir: Zoutendijk R.. VIRGIL surveillance study group Hepatology 2011) or is only suggested by some experts at week 48. In addition, it was noted that the patient population selected represents the vast majority of the patients who would be seen in clinical practice and would better benefit from treatment with tenofovir or entecavir. Also, the intensification strategy as proposed at week 24 if undetectable serum HBV DNA are not achieved is still under development. Therefore, the CHMP did not consider the MAH proposal to delineate the population appropriate. It agreed that initiation of treatment with telbivudine can be regarded as a downgraded option for the management of HBV-infected patients comparing to other medicinal products with high potency and high genetic barrier such as tenofovir or entecavir. In the view of this confirmed low genetic barrier to resistance, put into perspective of the newly approved medicinal products with a better resistance profile as well as the telbivudine safety concerns (see below Clinical Safety), the CHMP requested clarification from the HIV/viral CHMP Advisory Group (SAG) on the role of  Sebivo in the treatment of HBV infected patients in Europe and the benefit/risk balance (see section 2.7 Overall conclusion and benefit risk balance hereafter) Medicinal product no longer authorised

## 2.4.2. Clinical safety

In this renewal application, the MAH has submitted:

<div style=\"page-break-after: always\"></div>

- -one summary bridging report (SBR) covering the period from 01 March 2007 to 30 June 2011,
- -one addendum report covering the period from 01 Mar 2011 to 30 Jun 2011,
- -a clinical overview for product license renewal,

In the period under the review the following PSURs were submitted and assessed by the CHMP:  PSUR 2 covering the period from 01 Mar 2007 to 31 Aug 2007  PSUR 3 covering the period from 01 Sep 2007 to 28 Feb 2008  PSUR 4 covering the period from 01 Mar 2008 to 31 Aug 2008  PSUR 5 covering the period from 01 Sep 2008 to 28 Feb 2009  PSUR 6 covering the period from 01 Mar 2009 to 31 Aug 2009  PSUR 7 covering the period from 01 Sep 2009 to 28 Feb 2010  PSUR 8 covering the period from 01 Mar 2010 to 31 Aug 2010  PSUR 9 covering the period from 01 Sep 2010 to 28 Feb 2011. Patient exposure During the period covered by this renewal, 256 010 patient treatment years have been exposed to telbivudine. An estimate of the patient exposure was calculated by the MAH based on kg of active substance sold and the defined daily dose (600 mg/day). From 01 March 2007 to 30 June 2011 a total of 56 066 kg of active substance have been sold. Medicinal product no longer authorised

<!-- image -->

| Period:                               | Patient treatment-years (PTY)   |
|---------------------------------------|---------------------------------|
| 2: 01 Mar 2007 to 31 Aug 2007         | 4 428                           |
| 3: 01 Sep 2007 to 28 Feb 2008 product | 11 816                          |
| 4: 01 Mar 2008 to 31 Aug 2008         | 19 290                          |
| 5: 01 Sep 2008 to 28 Feb 2009         | 26 379                          |
| 6: 01 Mar 2009 to 31 Aug 2009         | 33 140                          |
| 7: 01 Sep 2009 to 28 Feb 2010         | 41 059                          |
| 8: 01 Mar 2010 to 31 Aug 2010         | 39 990                          |
| 9: 01 Sep 2010 to 28 Feb 2011         | 44 721                          |
| AR: 01 Mar 2011 to 30 Jun 2011        | 35 187                          |
| Total                                 | 256 010                         |

The MAH did not provide a layout of the patient exposure by formulation (film coated tablet or oral solution) and by region.  However, the data provided in the last PSUR (PSUR 9) showed that the patient exposure to film coated tablets remained low in European countries (2.2%, 984 PTY) while the exposure in China represented alone nearly 76% (34 270 PTY) of the total worldwide patient exposure to this product. In the European countries the exposure was the following (exposure in PTY): Austria: 68, Bulgaria: 21, Croatia: 12, France: 9, Germany: 156, Greece: 222, Italy: 405, Netherlands: 15, Norway: 2, Romania: 2, Slovenia: 1, Spain: 60, Sweden: 2, Turkey 4, and the UK: 5. The total patient exposure to oral formulation was 5.18 PTY and concerned Germany.

<div style=\"page-break-after: always\"></div>

## 2.4.2.1. Cumulative experience from 01 March 2007 until 30 June 2011

Globally, the main safety concerns of telbivudine in HBV-infected patients are represented by the risk of myopathy, peripheral neuropathy and rhabdomyolysis (and lactic acidosis as secondary events). These safety issues are reflected in the SmPC of Sebivo and the MAH closely monitors these issues in the PSURs. Beside the above safety issues, hypersensitivity reactions, ALT flares, fertility disorders and cases suggesting lack of efficacy and/or drug resistance information are closely monitored by the MAH.

<!-- image -->

|                       | Serious   | Serious   | Non-serious   | Non-serious   | Grand Total   |
|-----------------------|-----------|-----------|---------------|---------------|---------------|
| Report type           | Unlisted  | Listed    | Unlisted      | Listed        | Listed        |
| Spontaneous HCP       | 583       | 799       | 226           | 281           | 1889          |
| Suspect Solicited HCP | 120       | 301       | 35            | 32            | 488           |
| HCP total             | 703       | 1100      | 261 longer    | 313           | 2377          |
| Spontaneous non-HCP   | 116       | 70        | 188           | 309           | 683           |
| Non-HCP total         | 116       | 70        | 188           | 309           | 683           |
| Grand Total           | 819       | 1170      | 449           | 622           | 3060          |

<!-- image -->

Period covered by the Summary Bridging Report from 01 March 2007 to 30 June 2011 The layout of the distribution of the ADRs reported from 01 March 2007 to 30 June 2011 is provided in the table below. Table 8. Distribution of ADRs from 01 March 2007 - 30 June 2011 Report type Spontaneous HCP Suspect Solicited HCP HCP total Spontaneous non-HCP Non-HCP total Grand Total The MAH provided the layout of the number of AEs of special interest in the period covered by this renewal as follows. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 9. Summary of cases retrieved by PSUR/safety finding

| Relevant safety finding   | PSUR 2   | PSUR 3   | PSUR 4   | PSUR 5   | PSUR 6   | PSUR 7   | PSUR 8   | PSUR 9   | AR   | Total   |
|---------------------------|----------|----------|----------|----------|----------|----------|----------|----------|------|---------|
| Identified risk*          |          |          |          |          |          |          |          |          |      |         |

Four-year data were pooled from patients (n=655) treated in NV-02B-007/GLOBE, NV-02B- 015 and CLDT600A2303 for up to 4 years with telbivudine. Over 4 years of continued therapy, 71% patients had grade 1-2 elevations and 15.9% (104/655) had grade 3 or 4 elevations. However, CK elevations were asymptomatic and transient (lasting 1-2 visits with a visit interval of 2-12 weeks for 97.5% of patients and most resolved spontaneously or returned to baseline levels (1.8% of patients had grade 3 or 4 elevations persisting ≥ 2 visits). On-treatment CK elevations were not predictive of muscle events.

Fatal cases In total there were 26 reports with fatal outcome. According to the MAH, alternative causes (underlying condition, multiple confounding factors, accident etc) were present in the majority of cases. The remaining cases did not provide sufficient information to allow an assessment. Creatine phosphokinase (CK) elevations In the period covered by the renewal a total of 205 reports of CK elevations were received, including 9 cases reported during the period covered by the addendum report. Cumulatively, 35 cases reported by Health Care Professionals (HCPs) were classified into CK-only category. CK elevations and muscle events One-year data were pooled from 4 telbivudine studies: NV-02B-007/GLOBE (n=680), NV- 02B-015 (n=167), CLDT600ACN03 (n=2206) and CLDT600A2410 (n=59). From 1-year pooled data, grade 3 or 4 CK elevations occurred in 4.4 % (136/3112) and myopathy/myositis in 0.4% (11/3112). All 11 cases resolved, including 2 patients who recovered without interrupting telbivudine treatment. Ten of the 11 cases resolved within 14-120 days and the remaining case showed evidence of myopathic process in EMG and muscle biopsy. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

A total of 0.46% (3/655) telbivudine-treated patients discontinued study drug due to CK elevation or muscle related adverse events during the 4 years follow-up in studies NV-02B-007 /GLOBE, NV-02B015 and CLDT600A2303 (CLDT600A2303 CSR).

Taken together, there is no uniform pattern to the degree or timing of CK elevations. In addition, the predisposing factors for the infrequent development of muscle-related events in telbivudine-treated patients are not known but do not appear to involve CK elevations.

The specific mechanisms underlying myopathy/myositis are unknown. CK elevations are not predictive of muscle events associated with telbivudine. Mitochondrial toxicity, another potential mechanism, has not been observed with telbivudine in preclinical studies.

Table 10. CK toxicity Grade 3 or 4 adjusted for baseline covariates by logistic regression in study NV02B-007 (GLOBE) at week 104 for telbivudine-treated group (Caucasian and Asian patients) Blood creatine phosphokinase increased is a common adverse reaction listed in the SmPC of Sebivo. Based on this new logistic regression analysis of grade 3 or 4 CK elevations by baseline covariates from study NV-02B-007/GLOBE, the MAH proposes in this renewal application to delete the SmPC statement that pre-treatment CK values and Caucasian race are predictive of CK elevations. The outcome was that neither baseline CK nor Caucasian race are predictive factors for grade 3 or 4 elevations by week 104 (both p&gt;0.05) (see also section 2.6 Change to Product Information hereafter). Rhabdomyolysis A total of 18 cases containing the Preferred Term 'Rhabdomyolysis' were received during the period under review including one case during the period covered by the addendum report. No reports of rhabdomyolysis were reported in the clinical program. The section 4.4 of the SmPC of Sebivo mentions that cases of rhabdomyolysis have been reported during post-marketing use of telbivudine. Additionally rhabdomyolysis is currently listed as an adverse reaction with an unknown frequency in section 4.8 of the SmPC. Myopathy / myositis A total of 271 cases of myopathy / myositis cases were retrieved during the review period including 12 cases reported during the period covered by the addendum report. These 271 cases included 46 cases of myopathy combined with peripheral neuropathy. Cumulatively, 145 cases reported by Health Care Professionals (HCP) were classified into Myo-only category and 46 cases in myopathy and peripheral neuropathy category. Medicinal product no longer authorised

Myopathy is listed as an uncommon adverse reaction in the SmPC of Sebivo .

<div style=\"page-break-after: always\"></div>

## Lactic acidosis

Thirty-two cases of lactic acidosis were identified during the review period including 2 cases reported during the period covered by the addendum report.  Lactic acidosis as a secondary event often associated with serious conditions (e.g. multiorgan failure or sepsis) is currently listed in section 4.8 of the SmPC.

Peripheral neuropathy (PN) During the period under review a total of 170 reports of peripheral neuropathy were received including 12 cases reported during the period covered by the addendum report. Cumulatively, 51 cases reported by HCP were classified into PN-only category. No new cases of peripheral neuropathy due to a combination use of Sebivo and pegylated interferon (or standard) were reported since PSUR 6. The risk of peripheral neuropathy with telbivudine, even in monotherapy is mentioned in the SmPC Sebivo. ALT flare A total of 46 reports of increased ALT were received during the review period including 4 cases reported during the period covered by the addendum report. After review by a hepatologist, only 2 of the 46 cases were assessed as an ALT 'flare'. Acute pancreatitis A total of 15 cases of acute pancreatitis were retrieved by the search performed by the MAH during the period covered by the renewal. However, in PSUR 3, although the search retrieved 11 cases, upon review there were no cases of pancreatitis. In the addendum report, upon review, only 1 case involved the pancreas, and described a 50-year-old female patient who experienced an asymptomatic increase in lipase during treatment with Sebivo. There were 2 reports during PSUR 5 received from HCPs and one report was made during PSUR 8. In this case, the patient received combination treatment of interferon alfa-2b and Sebivo, which is now contra-indicated. Hypersensitivity reactions A total of 46 reports of hypersensitivity reactions were reported during the review period. The majority of the reports were related to various underlying conditions and did not reflect hypersensitivity in nature. There is no evidence that Sebivo is associated with severe hypersensitivity reaction. Mitochondrial toxicity As cases of myopathy, peripheral neuropathy and rhabdomyolysis have been reported with use of telbivudine, it was suggested that product could be associated to a risk of mitochondrial toxicity. Preclinical studies of mitochondrial toxicity were performed to address requests to provide additional information on muscle events and peripheral neuropathy (described in the assessment report FU2 019.7). Mitochondrial toxicity was not observed in preclinical studies. Fertility disorders A total of 4 reports of fertility disorders were received during the review period, none of them has been reported during the period covered by the addendum report. In all cases there was insufficient information to make a medical assessment. Medicinal product no longer authorised

## Cardiac repolarization

A thorough QT/QTc Study of telbivudine has been carried out in healthy subjects. The results of the study were published by Poordad et al 2009 and are as follows:

<div style=\"page-break-after: always\"></div>

- None of the changes in QTcF for either dose of telbivudine (600 and 1800mg) exceeded 5 msec, and none of the associated upper 1-sided 95% confidence intervals exceeded the limit of 10 msec.
- There was no increase in QTcF with increasing plasma telbivudine. The supratherapeutic dose of telbivudine was well tolerated with a safety profile similar to the clinical dose despite a 3-fold increase in plasma exposure.

<!-- image -->

| no   |
|------|

The results of GFR analysis confirmed the overall renal tolerance of telbivudine. According to the MAH, it may therefore be concluded that telbivudine is a safe renal drug. Renal function steadily improved in patients receiving telbivudine, with a significant improvement starting during the second year of treatment and largest improvement after 4 years. The apparent benefit of telbivudine in improving renal function could reflect both the recovery of liver synthetic dysfunction and lack of drug nephrotoxicity.

This study met the criteria (ICH-E14) for a negative thorough QT study. Renal function Renal toxicity is neither an identified risk nor a potential risk of telbivudine treatment. No renal toxicity has been previously reported with telbivudine. Glomerular Filtration Rate (GFR) was assessed at baseline and on treatment in 5 telbivudine clinical trials (NV-02B-007/GLOBE, CLDT600A2301, CLDT600A2303, CLDT600A2410 and CLDT600ACN03). GFR was calculated using the MDRD equation, which is considered to be an accurate index to evaluate GFR in patients with liver disease. According to the MAH, results show that telbivudine treatment is associated with a consistent improvement of GFR from baseline in both compensated and decompensated CHB patients. This improvement was seen in patients receiving either telbivudine monotherapy (all 5 studies) or LDT + tenofovir (TDF) combination therapy (study CLDT600A2410) (Table 4-16). In contrast, worsening of GFR was seen in patients treated with lamivudine (LAM). Table 11. Summary of calculated GFR (MDRD equation) at baseline and change from baseline in Sebivo clinical studies Medicinal product no longer authorised

However, in agreement with the SAG advice, the CHMP is of the opinion that the proposed MAH's beneficial claim of Sebivo on the renal function, measured as an improvement of the GFR,  lacks of

<div style=\"page-break-after: always\"></div>

biological plausibility and would need to be better substantiate to considered and reflected in the Product Information.

In this view, the MAH noted that CHMP recommendations to consider additional non clinical investigation, with adequate methodology on the protective effect of telbivudine on the renal toxicity of tenofovir as well as the recommendation to clarify and show how to substantiate the question on whether the use of tenofovir with telbivudine might be of interest as compared to tenofovir alone.

<!-- image -->

The MAH performed an analysis of the telbivudine clinical safety database and post-authorization exposure data including spontaneous reports, unpublished and published reports to assess the outcomes of newborns exposed in utero to telbivudine (Trylesinski et al 2010). As of 31-Aug-2009, 176 pregnancies were identified (132 prospectively and 44 retrospectively). Information on outcomes was available for 62% of the pregnancies. Of the 109 pregnancies, 28% ended in abortion (8 spontaneous, 22 induced; 80% in the first trimester) and congenital abnormalities were detected in 2.5% of the remaining pregnancies that resulted in live births. This rate of birth defects (2.5%) in live newborns exposed to telbivudine in utero is similar to that reported by the Centre for Disease Control, USA for the general population (2.72 per 100 live births).

Lack of Efficacy/Resistance: As discussed above in section 2.4.1 Clinical Efficacy, new data on the analysis of resistance development showed that the risk of resistance for telbivudine remains a concern and is likely to be approx 10-fold higher as compared to that with entecavir. Pregnancy and newborns During the period covered by the addendum report there were 18 prospective reports of drug exposure during pregnancy. Cumulatively there have been 196 prospective and 64 retrospective cases of pregnancy. Table 12. Summary of pregnancy outcomes Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

The CHMP noted that pregnancy outcomes remain unknown in a high number of cases, leading difficulties to draw reliable conclusion. As already mentioned in the SmPC, Sebivo should be used during pregnancy only if the benefit to the mother outweighs the potential risk to the foetus.

## Actions taken for safety reasons

<!-- image -->

|                       | Serious          | Serious   | Non-serious   | Non-serious   | Grand Total   |
|-----------------------|------------------|-----------|---------------|---------------|---------------|
| Report type           | Unlisted product | Listed    | Unlisted      | Listed        |               |
| Spontaneous HCP       | 4                | 4         | 7             | 8             | 23            |
| Suspect Solicited HCP | 0                | 10        | -             | -             | 10            |
| HCP total             | 4                | 14        | 7             | 8             | 33            |
| Spontaneous non-HCP   | 3                | 3         | 7             | 17            | 30            |
| Non-HCP total         | 3                | 3         | 7             | 17            | 30            |
| Grand Total           | 7                | 17        | 14            | 25            | 63            |

| MedDRA SOC Cardiac disorders Gastrointestinal        | HCP reports   | HCP reports                                                           | Non-HCP reports   | Non-HCP reports        |
|------------------------------------------------------|---------------|-----------------------------------------------------------------------|-------------------|------------------------|
| MedDRA SOC Cardiac disorders Gastrointestinal        | PTs Nb        | PTs reported ≥ 2 times                                                | PTs Nb            | PTs reported ≥ 2 times |
|                                                      | 2             |                                                                       | 0                 |                        |
| disorders                                            | 4             |                                                                       | 5                 | Dyspepsia (2)          |
| General disorders and administration site conditions | 17            | Asthenia (3), Drug interaction (2), Fatigue (3), Feeling abnormal (2) | 6                 | Asthenia (2), Pain(2)  |

During the period covered by the PSUR 3 (01 Sept 2007 to 28 Feb 2008), an increased risk of developing peripheral neuropathy was observed in chronic hepatitis B patients treated with Sebivo and pegylated interferon alfa-2a in a well controlled pilot clinical trial. The combination arm of this trial was permanently discontinued during the period covered by this report due to this increased risk of peripheral neuropathy. The Product Information was updated (variation II-03 adopted in January 2008) and a global Dear Healthcare Professional Communication (DHPC) was prepared for distribution by the MAH to inform prescribing physicians of this event. 2.4.2.2. Report of post marketing experience from 01 March 2011 to 30 June 2011 In addition, the MAH submitted within the renewal dossier one addendum report covering the period from 01 March 2011 to 30 June 2011. Overview of adverse reactions A total number of 63 cases were reported during the period covered by the addendum report. Among them 7 were serious unlisted cases. Among the 63 cases, there were 33 reports received from HCPs and 30 reports received from non-HCPs. The layout of the 63 reports is summarized in the table below. Table 13. Overview of reported cases by report type The distribution of adverse reactions reported with Sebivo by MedDRA System Organ Class in the addendum report is presented in the table below. Table 14. Distribution of ADRs in the addendum report (01 March 2011 - 30 June 2011) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| Hepatobiliary disorders                         |   1 |                                                                                                                                                     |   0 |                                              |
|-------------------------------------------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------|-----|----------------------------------------------|
| Infections and infestations                     |   3 | Hepatitis B (2)                                                                                                                                     |   0 |                                              |
| Injury, poisoning and procedural complications  |   7 | Drug exposure during pregnancy (6)                                                                                                                  |  15 | Drug exposure during pregnancy (15)          |
| Investigations                                  |  33 | Alanine aminotransferase increased (2), Blood creatine phosphokinase increased (5), Blood lactic acid increased (2), Hepatitis B DNA, increased (6) |   7 | Blood creatine phosphokinase increased (4)   |
| Metabolism and nutrition disorders              |   4 |                                                                                                                                                     |   0 |                                              |
| Musculoskeletal and connective tissue disorders |  17 | Back pain (2), Muscular weakness (4), Myalgia (3), Pain in extremity (2)                                                                            |   5 | Myalgia (3) authorised                       |
| Nervous system disorders                        |  12 | Hypoaesthesia (3), Neuropathy peripheral (4)                                                                                                        |   7 | Hypoaesthesia (4), Neuropathy peripheral (2) |
| Pregnancy, puerperium and perinatal conditions  |   2 | Normal newborn (2)                                                                                                                                  |   2 |                                              |
| Psychiatric disorders                           |   1 |                                                                                                                                                     |   1 |                                              |
| Renal and urinary disorders                     |   4 |                                                                                                                                                     |   1 |                                              |
| Respiratory, thoracic and mediastinal disorders |   3 | longer                                                                                                                                              |   2 | Dyspnoea (2)                                 |
| Skin and subcutaneous tissue disorders          |   2 | Rash (2)                                                                                                                                            |   1 |                                              |
| Social circumstances                            |   1 |                                                                                                                                                     |   0 |                                              |
| Total number of events                          | 113 |                                                                                                                                                     |  52 |                                              |

The CHMP agrees that the safety profile of telbivudine, mainly characterized by occurrence of muscular disorders, needs to be kept under close monitoring and that the MAH should carry on submitting PSUR every 6 months.

The most frequently adverse events concerned the SOC 'Investigations' (n=40), followed by the SOC' General disorders and administration site conditions' (n=23) and the SOC 'Musculoskeletal and connective tissue disorders' (n=22), and the SOC 'Injury, poisoning and procedural complications' (n=22). It is noteworthy that muscular-related adverse events (CPK increases + muscular disorders) are the most commonly reported adverse events with telbivudine, illustrating that muscle is the main target for drug toxicity. Although telbivudine and lamivudine are close on a virological point of view, CPK increases+ muscles disorders constitute a clear differential of risk between telbivudine and lamivudine. Discussion and Conclusion on Safety Beside the confirmed issue of increased resistance, the main safety concerns of telbivudine in HBVinfected patients are represented by the high risk of myopathy, myalgy, peripheral neuropathy and rhabdomyolysis (and lactic acidosis as secondary events). These issues are reflected in the SmPC of Sebivo and the MAH should continue to closely monitor these issues in the next PSURs. In addition, hypersensitivity reactions, ALT flares, fertility disorders and cases suggesting lack of efficacy and/or drug resistance information should continue to be closely monitored. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 2.5. Risk management plan

During the renewal procedure, the MAH submitted an updated risk management plan, which included a risk minimisation plan as follows.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 15. Summary of the risk management plan

<!-- image -->

<div style=\"page-break-after: always\"></div>

| Safety issues                                                                                                              | Agreed pharmacovigilance activities                                                                                                                                                                                                                 | Agreed risk minimisation activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Peripheral neuropathy (PN)                                                                                                 | Routine pharmacovigilance activities including cumulative analysis in PSUR. PN-like SAEs from clinical Novartis- sponsored trials and PN-like SRs are being followedup using a targeted follow-up questionnaire.                                    | current RMP. In line with these activities, a Patient Support Program (PSP) called HOPEs, a website based program in China, in which the goal is to improve compliance of Hepatitis B patients. This is a nation-wide public benefit program initiated and owned by China Foundation of Hepatitis Prevention and Control. Novartis China supports this program in order to ensure all Hep B patients receive a follow-up by their physician and receive a medical advice in case of changes in concurrent medications or new treatments [SPC section 4.3 (Contraindication)] [SPC section 4.4 (Special warnings and precautions for use)] [SPC section 4.8 (Undesirable effects)] The pilot trial CLDT600A2406 was terminated and all patients, specifically those who developed PN were followedup. A DHCP letter was agreed with CHMP and dispatched to prescribing physicians in all countries where telbivudine was launched depending on local regulatory requirements. All longer |
| Alanine aminotransferase (ALT) flares                                                                                      | Routine Pharmacovigilance activities including cumulative analysis in PSUR. no                                                                                                                                                                      | a patient Medication Guide for the US. [SPC section 4.4 (Special warnings and precautions for use)] [SPC section 4.8 (Undesirable effects)]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Lack of efficacy (with/ without antiviral resistance development)                                                          | Routine Pharmacovigilance activities including cumulative analysis in PSUR. Reporting of resistance data from ongoing trials: CLDT600A2303 CLDT600A2410 product                                                                                     | [SPC section 4.4 (Special warnings and precautions for use)] [SPC section 5.1 (Pharmacodynamic properties)]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Peripheral neuropathy for the combination of telbivudine with other interferon (than pegylated interferon alfa-2a)         | CLDT600A2409 Routine Pharmacovigilance activities including cumulative analysis in PSUR. SAEs from clinical Novartissponsored trials and SRs are being followed-up using a targeted follow-up questionnaire checklist. Pilot Drug Utilization Study | SPC section 4.3 (Contraindication) [SPC section 4.4 (special warnings and precautions for use)] [SPC section 4.5 (interactions with other medicinal products and other forms of interaction)].                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Lactic acidosis with/ without hepatic steatosis (Class effects of nucleoside analogs) Acute pancreatitis (Class effects of | Routine Pharmacovigilance activities including cumulative analysis in PSUR                                                                                                                                                                          | [SPC section 4.4 (Special warnings and precautions for use)] [SPC section 4.8 (Undesirable effects)] [SPC section 5.1 (Pharmacodynamic properties)]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| nucleoside analogs) Hypersensitivity reactions Maternal and fetal/ child outcomes                                          | Routine Pharmacovigilance activities including cumulative analysis in PSUR                                                                                                                                                                          | [SPC section 4.4 (Special warnings and precautions for use)]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|                                                                                                                            | Routine Pharmacovigilance activities including cumulative analysis in PSUR Routine Pharmacovigilance activities including cumulative analysis in PSUR Novartis has joined the APR: all pregnancies occurring in clinical trials or                  | [SPC section 4.8 (Undesirable effects)] [SPC section 4.6 (Pregnancy and lactation)] All pregnancy cases and outcomes are reported to the Anti-retroviral pregnancy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Fertility disorders                                                                                                        | reported to the APR Routine pharmacovigilance activities including cumulative analysis in PSUR                                                                                                                                                      | [SPC section 4.6 (Pregnancy and lactation)] [SPC section 5.3 (Preclinical                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| Safety issues                                                                                           | Agreed pharmacovigilance activities                                                                                                                   | Agreed risk minimisation activities                                                                                                                                                                                         |
|---------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                         |                                                                                                                                                       | safety data)]                                                                                                                                                                                                               |
| Drug-drug interaction between telbivudine and pegylated interferon alfa-2a HIV/HBV co-infected patients | Routine pharmacovigilance activities including cumulative analysis in PSUR Routine pharmacovigilance activities including cumulative analysis in PSUR | [SPC section 4.5 (Interaction with other medicinal products and other forms of interaction)] [SPC section 4.4 (Special warnings and precautions for use)] Study CLDT600A2202 to be conducted in HBV/HIV coinfected patients |

In addition, also in section 5.1 Pharmacodynamic properties , in line with the refusal of the initial MAH proposal of baseline criteria to define a population with lower resistance risk, a proposal to reflect the resistance data according to restricted baseline criteria and week 24 responses (based on retrospective analysis in NV-02B-007/GLOBE study) was not accepted as not informative and potentially misleading.

The CHMP, having considered the data submitted, was of the opinion that the proposed pharmacovigilance activities were adequate to monitor the safety of the product. 2.6. Changes to the product information As presented above, in this renewal application, the MAH proposed changes to the Product Information (PI), which were reviewed during the assessment of this renewal application. In particular, as per the conclusion of the post-authorisation measure 050 and in order to improve benefits while minimizing risk of resistance development, the MAH proposed to narrow the Sebivo indication according to baseline HBV DNA/ALT levels and Week 24 on-treatment response with treatment intensification. In line with the SAG minutes &amp; answers (meeting of 9 January 2012) and as discussed above in 'Conclusion and discussion on efficacy', the CHMP did not consider this proposal appropriate but considered that Sebivo has a role in clinical practice for patients who are unable to tolerate entecavir and tenofovir due to side effects and that it should be a therapeutic option when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. Accordingly, it was agreed to amend the section 4.1 Therapeutic indications as follows: 4.1 Therapeutic indications Sebivo is indicated for the treatment of chronic hepatitis B in adult patients with compensated liver disease and evidence of viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis. Initiation of Sebivo treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. See section 5.1 for details of the study and specific patient characteristics on which this indication is based. It was agreed that, in section 5.1 Pharmacodynamic properties, the initial proposed statement on the improvement of the GFR should not endorsed as lacking of biological plausibility and not sufficiently demonstrated. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Other SmPC updates, based on the reviewed efficacy and safety data over the reporting renewal period, were proposed, reviewed and agreed by the CHMP, including inclusion of the 208-week data on off-treatment sustained efficacy results (section 5.1), liver histology results (section 5.1) or deletion of the statement that pre-treatment CK values and Caucasian race are predictive of CK elevation (section 4.8).



In addition, changes were made to the PI to bring it in line with the current Agency/QRD template, SmPC guideline and other relevant guideline(s), which were reviewed by QRD and accepted by the CHMP. In addition, the list of local representatives in the PL has been revised to amend contact details for the representatives of Poland and Romania. 2.7. Overall conclusions and benefit risk balance Sebivo has been approved in Europe for the treatment of HBV infection in April 2007. Already at the time of the initial MA, the benefit/risk of the drug was considered as borderline positive since telbivudine was considered to be a 'lamivudine-like' antiviral that was not deprived of adverse effects (signal on muscular disorders was identified). Since the initial MA, long-term data were gained from follow-up studies. These data confirm the low genetic barrier of the drug with follow-up studies showing that resistance developed at high rate over time in patients that received telbivudine (40% in HbeAg positive and 20% in HbeAg negative patients at 4 years). Even though the resistance rate is less than that of lamivudine, antiviral resistance remains a major limitation of telbivudine treatment. In addition, these data highlight that another important limitation of telbivudine is its safety profile, mainly characterized by occurrence of muscular disorders. Whereas CPK elevations mostly asymptomatic had been reported during the clinical development, clinical cases of myalgia, myopathy as well as rhabdomyolysis have now emerged. Cases of peripheral neuropathy have also been reported. Moreover, since the MA of Sebivo was granted, the standard of care has evolved. Two medicinal products with both high potency and high genetic barrier to resistance have become the 'gold standard' for the treatment of chronic hepatitis B infection in Europe. They are recommended as firstline monotherapy in EASL guidelines and have become the medicinal products of choice for initiation of treatment. Given these updated data and therapeutic evolution, the CHMP considered the input of the Scientific Advisory Group (SAG) was necessary during the renewal procedure in order to determine the role of telbivudine in the treatment of HBV patients in Europe and whether it is possible to delineate a patient population (niche) where the benefit/risk of telbivudine could be considered as favourable. In this context the following questions were put to the SAG:  Is there still a role for telbivudine in the treatment of HBV infected patients in Europe? If so, for which patients groups would telbivudine still be a proper treatment. Given the low genetic barrier to resistance of telbivudine and the safety profile, it is under consideration whether the risks related to the use of this compound do not outweigh the benefits of its use. What is, from a clinical practice perspective, the view from the HIV / AV SAG on this point. Medicinal product no longer authorised

On 9 January 2012, the SAG reviewed the available data concerning Sebivo.

<div style=\"page-break-after: always\"></div>

The SAG agreed that, due to the low genetic barrier to resistance of Sebivo, the benefit risk balance could only be considered positive when the use of an alternative antiviral agent with a higher genetic barrier is not available or appropriate.

The SAG also commented that the effect of telbivudine on GFR, for which the MAH has initially proposed a beneficial effect claim, should be further and robustly demonstrated

In addition, it was noted that Sebivo may be used for treatment of women of child-bearing age who are not compliant with contraception and as such who may not be able to take entecavir or for pregnant women with renal insufficiency for which tenofovir is not an option. However, so far, safety data in pregnancy only consist in pre-clinical data and one investigator lead study not yet fully assessed. In the view of the public health need for HBV treatment option in pregnant women in Europe, the SAG recommended that the MAH should provide more data to substantiate the safety of telbivudine in pregnancy. Accordingly, the Sebivo RMP has been updated to include data collection report from post-marketing surveys in women exposed to telbivudine during pregnancy. Overall, CHMP endorsed the outcome of the SAG and, and in line with the recommendations, did not agree with the MAH's initial proposed indication restriction (baseline criteria of HBV DNA &lt;9 log10 copies/ml and ALT&gt;2x ULN in HBe Ag pos and &lt;7 log10 copies/ml in HBe neg with intensification at week 24) as a way to overcome the acknowledged low genetic barrier of this drug. Indeed, even under these proposed restricted conditions, the resistance rates observed with telbivudine are higher than those with tenofovir and entecavir. In addition, resistance data are only available for 2 years for the restricted population while quite reassuring 5 years data are available for tenofovir and entecavir. It is also noted that, according to an epidemiological survey in EU, these population criteria are not so restrictive since the vast majority of EU patients (more than 80%) match these criteria. In conclusion, the CHMP agreed that telbivudine has a role in clinical practice for patients for whom an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. It was agreed to amend the Sebivo indication to recommend the initiation of Sebivo treatment only when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. The CHMP also endorsed the SAG concern regarding the lack of data for the use of telbivudine during pregnancy since there is a public health need for treatment options in pregnant women. It noted that the MAH updated accordingly the Sebivo RMP to include data collection report from post-marketing surveys in women exposed to telbivudine during pregnancy. Regarding safety, the CHMP agreed that Sebivo needs to be kept under close monitoring, mainly due to the risk of resistance/lack of efficacy and the occurrence of muscular disorders. The MAH will continue to submit 6 monthly PSUR's and an additional 5 year renewal based on these Pharmacovigilance concerns is warranted. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 3. Recommendations

Based on the CHMP review of data on quality, safety and efficacy, including all variations introduced since the marketing authorisation was granted, the CHMP considers by consensus that the risk-benefit balance of Sebivo in the treatment of chronic hepatitis B in adult patients remains favourable and therefore recommends the renewal of the marketing authorisation

Not applicable

## Grounds for one additional renewal

Conditions or restrictions regarding supply and use Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2). Conditions and requirements of the marketing authorisation Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance presented in Module 1.8.1. of the Marketing Authorisation, is in place and functioning before and whilst the medicinal product is on the market. Risk management system (RMP) The MAH shall perform the pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in the RMP presented in Module 1.8.2 of the Marketing Authorisation and any subsequent updates of the RMP agreed by the Committee for Medicinal Products for Human Use (CHMP). As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR). In addition, an updated RMP should be submitted:  When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities  Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached  at the request of the European Medicines Agency PSUR The PSUR cycle for Sebivo should follow a half-yearly cycle until otherwise agreed by the CHMP. Conditions or restrictions with regard to the safe and effective use of the medicinal product The CHMP recommends that one additional five-year renewal be required. This is based on the following pharmacovigilance grounds: Medicinal product no longer authorised

Based on the review of the available information, the CHMP was of the opinion that the quality, the safety and the efficacy of this medicinal product continues to be adequately and sufficiently

<!-- image -->

<div style=\"page-break-after: always\"></div>

demonstrated within the restricted indication and therefore considered that the benefit/risk balance of Sebivo remains favourable.

However specific issues related to pharmacovigilance remain, notably the resistance of this drug of low genetic barrier as well as the growing evidence of muscular toxicity during the first 5 years period justify keeping the Marketing Authorisation of this medicinal product under close scrutiny.

Based upon the above defined pharmacovigilance issues of Sebivo, the CHMP decided that the MAH should continue to submit 6 monthly PSURs and that the MAH should submit one additional renewal application in 5 years time. Amendments to the marketing authorisation In view of new data submitted as part of the renewal application, the CHMP recommends amendments to the Annexes I, II, IIIA and IIIB. The CHMP requested the above mentioned changes on safety grounds and in order to maintain the positive risk-benefit balance of the product. Medicinal product no longer authorised